Octave Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 95

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $10M

  • Investors
  • 14

Octave General Information

Description

Developer of a clinical platform designed to generate, analyze, and combine data to create a new paradigm of multiple sclerosis care. The company's platform offers an integrated and multi-dimensional approach to reducing the total cost of care by optimizing healthcare medications and utilization, enabling the pharma industry to optimize the entire lifecycle of drug discovery, clinical trials, and post-marketing with real-world evidence.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Corporate Office
  • 1440 O'Brien Drive
  • Suite B
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Octave Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Octave Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 15-Nov-2023 $10M 000.00 Completed Generating Revenue
3. Later Stage VC (Series B) 26-Jul-2023 0000 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 12-Jul-2018 $14M $16.5M 0000 Completed Generating Revenue
1. Seed Round 13-Sep-2017 $2.5M $2.5M 00.000 Completed Generating Revenue
To view Octave’s complete valuation and funding history, request access »

Octave Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 2,500,000 $0.000100 8% $1 $1 1x $1 8.31%
To view Octave’s complete cap table history, request access »

Octave Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a clinical platform designed to generate, analyze, and combine data to create a new paradigm of multiple sc
Decision/Risk Analysis
Menlo Park, CA
95 As of 2023
000.00
0000000000 000.00

000000

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
00000 0000000000 000
Oakland, CA
00 As of 0000
000.00
000000 - 000 000.00

000000

bore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
00000 0000000000 000
Toronto, Canada
00 As of 0000
00000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Octave Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fabric Genomics Venture Capital-Backed Oakland, CA 00 000.00 000000 - 000 000.00
MEMOTEXT Formerly Accelerator/Incubator backed Toronto, Canada 00 00000000000
InsightRx Venture Capital-Backed San Francisco, CA 00 000.00 0000000000 0 000.00
Tempus Venture Capital-Backed Chicago, IL 0000 00.000 000000000000 00.000
COTA Private Equity-Backed New York, NY 000 00000 0000000 0000 00000
You’re viewing 5 of 36 competitors. Get the full list »

Octave Patents

Octave Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230266342-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020 000000000
CA-3189918-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020 000000000
AU-2021336985-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020 000000000
EP-4208869-A1 Biomarkers for predicting multiple sclerosis disease progression Pending 04-Sep-2020 000000000
CA-3189916-A1 3d graph visualizations to reveal features of disease Pending 01-Sep-2020 G06T7/0016
To view Octave’s complete patent history, request access »

Octave Executive Team (10)

Name Title Board Seat Contact Info
Doug Biehn Chief Executive Officer & President
Melinda Thomas Co-Founder & Chief Operating Officer
Erwan Rivet Chief Technology Officer
Mike Edgeworth MD Chief Population Health Officer
William Hagstrom Founder & Chairman
You’re viewing 5 of 10 executive team members. Get the full list »

Octave Board Members (7)

Name Representing Role Since
Andrea Jackson Northpond Ventures Board Member 000 0000
Brook Byers Ph.D Kleiner Perkins Board Member 000 0000
George Scangos Ph.D Self Board Member 000 0000
Grant Heidrich III Self Board Member 000 0000
Michael Pellini MD S32 Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Octave Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Octave Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Michael J. Fox Foundation Limited Partner 000 0000 000000 0
Casdin Capital Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
dRx Capital Novartis Venture Capital Minority 000 0000 000000 0
Hikma Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »